ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
4 announcements with these filters
Q1FY27 was challenging with Revenue/PAT declining 42%/68% YoY due to subdued European demand and termination of a distributor agreement. Management shifted focus to direct customer engagement and CRAMS projects.
Shree Ganesh Remedies reported Q4 FY26 revenue of INR 33.20 cr (up 36% YoY). Management characterized FY26 as a consolidation year, focusing on CRAMS pilot trials and capacity expansion.
Management characterized FY26 as a consolidation year, focusing on groundwork for CRAMS. While Q4 showed strong sequential recovery, full-year growth remained flat as the company pivoted from generic domestic markets to specialized global molecules.
Shree Ganesh Remedies reported stagnant FY26 revenue of ₹109.3cr with a 23% PAT decline to ₹17.8cr. Focus remains on scaling CRAMS and specialty chemicals via expansion.